Affinity Asset Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Affinity Asset Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-250,000	Closed	-$5.39M	–	109
2025 Q4	$5.39M	Buy	+250,000	New	+$4.85M	0.31%	63

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Affinity Asset Advisors's AVDL Position: Q1 2026 in Review

Affinity Asset Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 250,000 shares — an estimated $5.39M sold.

Affinity Asset Advisors first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $5.39M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Affinity Asset Advisors reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Affinity Asset Advisors sold 250,000 Avadel Pharmaceuticals shares in Q1 2026, an estimated $5.39M.
Affinity Asset Advisors first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Affinity Asset Advisors's Avadel Pharmaceuticals position peaked at $5.39M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.